Bio-Rad Takes Option to Commercialize Axis-Shield's HBP Sepsis Marker | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Axis-Shield said today that it has signed an agreement with Bio-Rad Laboratories for an option to commercialize heparin binding protein as a marker of severe sepsis.

Under the terms of this agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally.

Additional terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.